Transdermal Rotigotine: A Clinically Innovative Dopamine‐Receptor Agonist for the Management of Parkinson's Disease

  title={Transdermal Rotigotine: A Clinically Innovative Dopamine‐Receptor Agonist for the Management of Parkinson's Disease},
  author={Jack J. Chen and David M. Swope and Khashayar Dashtipour and Kelly E. Lyons},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  • Jack J. Chen, D. Swope, K. Lyons
  • Published 1 December 2009
  • Medicine, Biology, Psychology
  • Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Rotigotine is a highly lipophilic dopamine‐receptor agonist and the first transdermally delivered agent to demonstrate efficacy and safety as monotherapy in early Parkinson's disease and to reduce “off” hours in levodopa‐treated patients with advanced Parkinson's disease. The rotigotine pharmacophore is nonergolinic and demonstrates high affinity for dopamine D2 and D3 receptors. With once‐daily application, the patch matrix provides continuous, nonfluctuating plasma drug levels at steady state… 
Rotigotine Transdermal Patch
Rotigotine offers a novel approach to the treatment of Parkinson’s disease and, given its ease of administration, efficacy in reducing disabling motor and non-motor symptoms, and acceptable tolerability profile, it has the potential to be an attractive treatment option for this highly debilitating disease.
Safety and Tolerability of Transdermal Rotigotine in a Clinical Practice Cohort for 2 Years
Rotigotine is safe and well tolerated when used to treat PD in routine clinical practice, and necessitated the discontinuation of rotigotine for application site reactions in fourteen patients.
Dopaminergic agonists in Parkinson's disease.
Dopaminergic agonists in Parkinson's disease
Introduction Rotigotine is a non-ergolinic dopamine receptor agonist indicated for the treatment of early and advanced-stage Parkinson's disease and moderate-to-severe idiopathic restless legs syndrome (LeWitt
Efforts were put to develop controlled release transdermal patches of Rotigotine using a novel hybrid technique that includes a combination of microreservoir system and adhesive dispersion system.
Current Status and Challenges in Rotigotine Delivery.
There are challenges that remain in other routes of rotigotine administration such as oral, parenteral and pulmonary whereby resolving these challenges will be beneficial to patients as they are less invasive and easy in terms of administration.
Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys.
  • Jingwei Tian, G. Du, X. Guan
  • Biology, Medicine
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • 2013
Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience
It is believed that the effective use of the rotigotine transdermal patch can address motor symptoms and a wide range of NMS, improving health-related QoL for patients with Parkinson's disease.
Low Doses of Rotigotine in Patients With Antipsychotic-Induced Parkinsonism
The results of this observational study suggest that low doses of rotigotine are well tolerated in patients with psychosis and are effective in neuroleptic-induced EPSs.
Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in SD rats.
  • L. Ye, X. Guan, Youxin Li
  • Biology
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • 2013


Safety, Tolerability, and Efficacy of Continuous Transdermal Dopaminergic Stimulation with Rotigotine Patch in Early-Stage Idiopathic Parkinson Disease
The data suggest that rotigotine is a safe, well-tolerated, and effective treatment for early-stage Parkinson disease.
The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease
Rotigotine can be characterized as a specific dopamine receptor agonist with a preference for the D3 receptor over D2 and D1 receptors in Parkinson's disease and possible other indications such as restless legs syndrome.
Continuous Transdermal Dopaminergic Stimulation in Advanced Parkinson's Disease
The data suggest that Rotigotine CDS is an effective treatment for advanced Parkinson's disease and permits patients to substantially lower L-Dopa doses without loss of antiparkinsonian efficacy.
Rotigotine transdermal patch in early Parkinson's disease: A randomized, double‐blind, controlled study versus placebo and ropinirole
The rotigotine transdermal patch represents an effective and safe option for the treatment of patients with early Parkinson's disease and the most common adverse events were application‐site reactions, nausea, and somnolence.
A controlled trial of rotigotine monotherapy in early Parkinson's disease.
  • Medicine, Psychology
    Archives of neurology
  • 2003
Rotigotine can be safely administered once daily transdermally and improves parkinsonian signs in patients with early PD.
Overnight Switch From Oral Dopaminergic Agonists to Transdermal Rotigotine Patch in Subjects With Parkinson Disease
Subjects and clinicians found the overnight switch to rotigotine convenient, well tolerated, and effective for control of PD signs and symptoms for subjects previously receiving low-to-moderate doses of oral dopaminergic agonists.
Rotigotine Transdermal Patch Enables Rapid Titration to Effective Doses in Advanced-Stage Idiopathic Parkinson Disease: Subanalysis of a Parallel Group, Open-Label, Dose-Escalation Study
The fast-titration regimen had a similar adverse event profile to slower titration, and allowed rotigotine to be introduced quickly, according to this subanalysis, which suggests thatrotigotine may be uptitrated more rapidly.
Advanced Parkinson disease treated with rotigotine transdermal system
Transdermal rotigotine significantly improved “off” time in subjects with Parkinson disease not optimally controlled with levodopa and was safe and well tolerated, with typical dopaminergic side effects and occasional application site reactions.
Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease
Transdermal rotigotine, in a continuous-dosing transdermal-patch formulation, when titrated to a dosage of 6 mg/24 h, was effective for the treatment of early-stage Parkinson disease in this trial.